Skip to main content

The development of an effective synthetic route of rilpivirine



Rilpivirine (RPV) was approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Significantly, rilpivirine is three fold more potent than etravirine. Once-daily, it is used with a low oral dose (25 mg/tablet), decreasing the drug administration and bringing a better choice to the patients. However, there are many shortcomings in the existing synthesis route of RPV, such as the high cost, prolonged reaction time and low yield (18.5%).


This article describes our efforts to develop an efficient and practical microwave-promoted method to synthesize rilpivirine using less toxic organic reagents and low boiling solvents. The last step's reaction time decreased from 69 h to 90 min through this optimized synthetic procedure, and the overall yield improved from 18.5 to 21%. In addition, the yield of intermediate 3 increased from 52 to 62% compared to the original patent.


Overall, through a series of process optimization, we have developed a practical synthesis method of rilpivirine, which is easy to scale with higher yield and shorter reaction time.


HIV-1 non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are an integral part of highly active antiretroviral therapy (HAART) due to its high tolerability and low toxicity. However, the rapid emergence of drug-resistant HIV-1 strains limited their clinical use [1,2,3,4,5,6,7]. Rilpivirine ((E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile), is a successful second-generation NNRTI of diarylpyrimidine family (Fig. 1), approved by the U.S. FDA in 2011 for the treatment of individuals infected with HIV-1. Rilpivirine has a high genetic barrier to form resistance mutations and generally requires multiple mutations to confer significant resistance [8,9,10]. Several research-scale synthetic methods have been reported for the preparation of rilpivirine. However, there are some shortcomings among the existing synthetic routes, such as low yield (18.5%), use of high boiling point solvent [(dimethoxyethane (DME), N-methylpyrrolidin-2-one (NMP), etc.) and toxic materials (acrylonitrile, etc.,)] which lead to a high price of rilpivirine. Therefore, a new synthetic route is needed urgently for a more economical, less toxic and more productive rilpivirine synthesis.

Fig. 1.

The chemical structure of rilpivirine approved by the U.S. FDA in 2011

Organic synthesis of rilpivirine

The current procedure for the synthesis of rilpivirine is mainly divided into three steps: (a) synthesis of (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile hydrochloride (intermediate 2); (b) synthesis of 4-((4-chloropyrimidin-2-yl)amino)benzonitrile (intermediate 3); (c) synthesis of rilpivirine (1).

Synthesis of (2E)-3-(4-amino-3,5-dimethylphenyl)prop-2-enenitrile hydrochloride (intermediate 2)

Scheme 1 illustrates the synthesis of intermediate 2. Initially, the Heck reaction was performed by allowing the reaction between 4-bromo-2,6-dimethylaniline (4) and acrylamide (5) under inert conditions to achieve (2E)-3-(4-amino-3,5-dimethylphenyl)prop-2-enamide (6). Dehydration of compound 6 by treating with POCl3 yielded (2E)-3-(4-amino-3,5-dimethylphenyl)prop-2-enenitrile (7). Finally, the desired intermediate 2 ((2E)-3-(4-amino-3,5-dimethylphenyl)prop-2-enenitrile hydrochloride) with 77% yield was achieved by treating compound 7 with HCl in diisopropyl ether under inert condition. The application of palladium acetate (67$/g, 1Pluschem) and tri-O-methylphenylphosphine (8$/g, A2B Chem) ligand has greatly improved the yield of trans-isomer. However, these two materials are relatively expensive to use in the industry and environmentally polluting [11, 12].

Scheme 1.

Synthesis of intermediate 2 from 5-bromo-2,4,6-trichloropyrimidine (4) and acrylamide (5) as starting materials [11]. Reagents and conditions: (i) Pd(OAc)2, P(C6H5CH3)3, Et3N, CH3CN, N2, 79 °C, overnight, 79.5%; (ii) POCl3, 0 °C, 30 min; 20 °C, overnight, 84%; (iii) EtOH, ((CH3)2CH2)2O, N2, 60 °C, 30 min; HCl, 2-propanol, 60 °C, 30 min, 77%

Scheme 2 also represents the successful synthesis of intermediate 2, and it differs from Scheme 1 by only starting materials and reagents used in the first step. Starting materials 4-iodo-2,6-dimethylaniline (8) and acrylonitrile (9) were treated by Heck reaction to obtain compound 7. Intermediate 2 was obtained by treating compound 7 with HCl in diisopropyl ether under inert condition with 64.5% yield. Although scheme 2 is shorter than Scheme 1 and palladium/carbon is recyclable and cheaper than palladium acetate, the acrylonitrile belongs to B-class organic toxicants. It is too toxic, dangerous and controlled by the public security department, restricting the commercial production [13, 14].

Scheme 2.

Synthesis of intermediate 2 from 4-iodo-2,6-dimethylaniline (8) and acrylonitrile (9) as starting materials [13]. Reagents and conditions: (i) CH3COONa, Pd/C, DMAC, N2, 140 °C, 21 h, 81%; (ii) EtOH, HCl, 2-propanol, 60 °C, 1 h, 64.5%

Synthesis of 4-[(4-chloropyrimidin-2-yl)amino]benzonitrile (intermediate 3)

Scheme 3 represents the chemical pathway for the preparation of intermediate 3 (4-[(4-chloropyrimidin-2-yl)amino]benzonitrile). The starting materials 2-thioxo-2,3-dihydropyrimidin-4(1H)-one (10) and iodomethane were blended in the presence of NaOH base to attain compound 11. Further, the nucleophilic substitution of 11 with p-aminobenzonitrile (12) in DME afforded compound 13(iia). Finally, the target intermediate 3 was obtained by chlorinating the hydroxy group of 13 with POCl3 under reflux conditions. This route's advantage is that the reaction step is simple and short, and the total yield is up to 47%, and the disadvantage is that the reaction produces methanethiol, which is highly toxic and smelly. Complete elimination of this odour is highly challenging, which may increase the cost of large-scale industrial production. In addition, the boiling point of DME used in the reaction process is too high [15]. So it has been reported that the step (ii) using the melting method also has a higher yield and shorter reaction time [16, 17]. However, there is no report on the influence of temperature and reaction time on the yield, the optimal reaction temperature and reaction time cannot be determined.

Scheme 3.

Synthesis of intermediate 3 from 2-thioxo-2,3-dihydropyrimidin-4(1H)-one (10) as starting material [15,16,17]. Reagents and conditions: (i) CH3I, NaOH, r.t., overnight, 88%; (iia) DME, reflux, 18 h, 68%; (iib) 180–190 °C, 10 h, 70–74%; (iic) 180 °C, 8 h, 73.6% (iii) POCl3, reflux, 20 min, 77%

Scheme 4 also illustrates the synthesis of intermediate 3, and the cyclization of starting material 1-(4-cyanophenyl)guanidine (14) with substituted diethyl malonate (15) in the presence of NMP and sodium acetate afforded compound 16 with pyrimidine moiety. The subsequent reaction of 16 with water, acetic acid, leads to 13, which further treated with POCl3 afforded the desired intermediate 3 by "one-pot method". Although it is a simple reaction with an overall yield of 58.5%, the starting material (14) is expensive, limiting the large-scale industrial application of this route [18].

Scheme 4.

Synthesis of intermediate 3 from 1-(4-cyanophenyl)guanidine (14) and diethyl 2-(ethoxymethylene)malonate (15) as starting materials [18]. Reagents and conditions: (i) NMP, AcONa, 100 °C, 1 h; (ii) H2O, 155–160 °C; AcOH, 130–150 °C, 76%; (iii) POCl3, reflux, 20 min, 77%

In Scheme 5, uracil's reaction with POCl3 leads to the formation of 2,4-dichloropyrimidine (18), which was further treated with sodium methoxide in methanol afforded 19. The acid-catalyzed nucleophilic addition between 19 and 4-aminobenzpnitrile in the presence of 2-toluenesulphonic acid in dioxane gave 4-[4-methoxypyrimidin-2-yl)amino]benzonitrile (20). The target intermediate 3 was achieved by reacting 20 with pyridine, followed by POCl3 under reflux condition. The reaction is relatively simple, but the process is too long and reducing the yields. Also, the highly toxic phosphorus oxychloride reagent is used repeatedly, which is harmful to the environment and public health. The entire route has a long reaction time and consumes a lot of energy, which is not suitable for industrial production [14].

Scheme 5.

Synthesis of intermediate 3 from pyrimidine-2,4(1H,3H)-dione (17) as starting material [14]. Reagents and conditions: (i) C6H5N(CH3)2, POCl3, 0 °C; reflux, 4 h, 43%; (ii) CH3OH, NaOCH3, rt, 14 h, 50%; (iii) 2-Toluene sulfonic acid, dioxane, 100–110 °C, 14 h, 55%; (iv) Pyridine, 150–160 °C, 3 h, 87%; (v) POCl3, 0 °C, reflux, 1 h, 75%

Synthesis of rilpivirine

Synthesis of the target compound rilpivirine (1) was achieved by allowing the reaction between (2E)-3-(4-amino-3,5-dimethylphenyl)prop-2-enenitrile hydrochloride (2) and 4-[(4-chloropyrimidin-2-yl)amino]benzonitrile (3) in acetonitrile under reflux condition for 69 h (Scheme 6, yield: 68.6%) [19]. This reaction's conditions are relatively simple, but the reaction time is longer, extending the industrial cycle production time and reducing the product's yield and quality. Also, it has been reported that NMP used as a solvent at 95 °C for 17 h to produce rilpivirine with 71.4% yield, wherein cis-isomer accounts for 0.7% [20]. However, it isn't easy to reclaim NMP in industrial production because of its higher boiling point.

Scheme 6.

Synthesis of rilpivirine from intermediates 2 and 3 [19, 20]

There are many shortcomings in the synthetic strategy of rilpivirine. Notably, (a) intermediate 2 was mainly obtained by Heck reaction, and the catalyst palladium acetate and its ligands used in this reaction are expensive; (b) the starting material (14) used for the preparation of intermediate 3 is relatively expensive and the reaction temperature is too high; (c) when uracil is used as a starting material, the synthetic route in Scheme 5 is rather tedious, and the final reaction yield is too low; (d): the final step in the synthesis of rilpivirine, is too long (69 h) and causing energy consumption. Hence there is an urgent need to find more efficient and practical methods for synthesizing rilpivirine in the pharmaceutical industry. Herein, we represent our efforts to develop an efficient synthetic route with increased overall yield and reasonable reaction time.

Results and discussion

A novel synthetic procedure for the rilpivirine is successfully demonstrated in six steps with improved yield (21%). The method (Scheme 7) is developed to generate laboratory-scale rilpivirine without using toxic reagents (acrylonitrile), and high boiling point solvents (NMP). This method aims to develop an efficient synthetic route for intermediate 3 and improve the reaction conditions for the nucleophilic substitution reaction in the last step. To achieve the desired intermediate 3, initially, a fusion reaction was carried out between 2-(methylthio)-4(3H)-pyrimidinone (11) and p-aminobenzonitrile (12) under an inert atmosphere, resulted in compound 13. After that, compound 13 reacted with POCl3 under reflux conditions to yield the target intermediate 3. As well as intermediate 2 was obtained as illustrated in Scheme 7. Finally, the nucleophilic substitution reaction between intermediates 2 and 3 through microwave-irradiation leads to the rilpivirine formation with improved yield (21%) and shorter reaction time (90 min).

Scheme 7.

The improved synthetic procedure of rilpivirine. Reagents and conditions: (i) Pd(OAc)2, P(C6H5CH3)3, CH3COONa, DMAC, N2, 130 °C, 24 h, 51%; (ii) POCl3, 40 °C 8 h; (iii) EtOH, HCl, acetyl chloride, 0 °C, 30 min, total yield of steps (ii) and (iii) 95%; (iv) N2, 160 °C, 2 h, 180 °C, 4 h, 70%; (v) POCl3, reflux 8 h, 89%; (vi) CH3CN, 140 °C, 90 min, 71%

Optimization of synthesis steps and process parameters of intermediate 13

The reaction for the synthesis of compound 13 was carried out through melting/fusion method with the temperature ranging from 160 °C to 200 °C. Herein, we investigated the effect of reaction temperature and reaction time on the yield of compound 13 (Table 1). During this process, the observations are: (1) when the reaction temperature was 160 °C, the reaction solution was completely solidified after 2 h, and the product yield was 64%; (2) when the temperature was 180 °C for 6 h, the product yield was 70%; (3) when the reaction temperature was 190 °C for 6 h, the product yield was 70.2%; (4) when the reaction temperature was 200 °C, no obvious increase in the yield was observed compared to the yield at 190 °C. To sum up, the reaction condition is selected to be 160 °C for 2 h, and then 180 °C for 4 h.

Table 1. Optimization of reaction temperature and time for compound 13 yield

Synthesis optimization of rilpivirine (1)

Considering the longer reaction time of the final step in the previous reports, we attempt to apply the microwave-assisted synthesis method in the amination step to shorten the reaction time and to improve the yield of rilpivirine. The orthogonal experiment investigated the effects of reaction solvent, temperature, pressure and reaction time on microwave-assisted amination yield.


Optimization of reaction solvent

Among the methods reported in the literature, the most commonly used solvents are acetonitrile and NMP. In the preliminary study, we conducted the reaction under atmospheric pressure (method A). When we led our first attempt, dioxane, acetonitrile, and NMP solvents were used. It was observed that the reaction with acetonitrile solvent provided good yields, NMP with moderate to good and with dioxane the reaction is not formed. However, when we tried to use these three kinds of solvents for microwave reaction, the reaction results were not satisfactory. Table 2 shows that although the microwave reaction can proceed smoothly, the microwave reaction yield is still far from the traditional heating conditions.

Table 2. Optimization of solvent for the synthesis of rilpivirine with better yield

Considering that different solvents are used as the reaction, none of the reactions was ideal. We speculated that the reaction temperature and time have a significant influence on the reaction yield. Since the acetonitrile yield as solvent was similar to NMP and considering industrial production cost, we choose low-boiling acetonitrile as the reaction solvent for further exploration. Therefore, a single variable method was applied to investigate the effect of reaction temperature and time on yield. The results are shown in Table 3.

Table 3. Optimization of reaction temperature and time

We can conclude that the yield was improved with the increased reaction time and temperature. But there is a decreasing tendency of the yield when the temperature is 150 °C and reaction time is more than 120 min. Accordingly, the amination reaction's optimized conditions were determined as follows: microwave-irradiation reaction with acetonitrile solvent at 140 °C for 90 min produced the amination product with 71% yield, which was higher than that of the traditional method (69%).


In conclusion, we provide a synthetic method for rilpivirine, an essential drug in the treatment of acquired immunodeficiency syndrome (AIDS). The experiment mainly optimized the route of rilpivirine and the key process parameters of each step by controlling the single variable method to determine the optimal experimental conditions. The total yield was improved from 18.5 to 21%, and the reaction time of the last step decreased from 69 h to 90 min. The details are as follows: (1) synthesis of 4-((4-hydroxypyrimidin-2-yl)amino)benzonitrile (13) the reaction was carried out at 160 °C for 2 h, and then the temperature was raised to 180 °C for 4 h. After the treatment, a small amount of N,N-dimethylformamide was added to dissolve the residues, subsequently, the mixture was filtered and washed with acetonitrile to give the product with 70% yield; (2) the total yield of the intermediate 3 increased from 52 to 62% compared to the original patent. The total synthesis yield of the intermediate 2 and rilpivirine is equivalent to original patents. (3) For the rilpivirine synthetic step, a microwave-irradiation method is selected instead of the traditional method in the original patent, and the yield of amination reaction is increased to 71%. Therefore, the total synthetic yield of rilpivirine risen from 18.5 to 21%. The method proceeded in six linear steps with a gram scale and did not use high toxicity starting materials and high boiling-point solvent. This efficient and environmental-friendly process and the optimum conditions for rilpivirine preparation may form the basis for future manufacturing route.

Experimental section

Thin-layer chromatography (TLC) was performed on Silica Gel GF254 for TLC (Merck), and spots were visualized by irradiation with UV light (λ = 254 nm). 1H NMR and 13C NMR spectra were recorded on a Bruker AV-400 NMR spectrometer or a Bruker Avance-600 NMR spectrometer using solvents as indicated. Chemical shifts were reported in δ values (ppm) with tetramethylsilane as the internal reference, and J values were reported in hertz (Hz). Melting points (m.p.) were determined on a micro melting point apparatus (TianJin Analytical Instrument Factory, Nankai, Tianjin, China). Mass spectra were recorded on an LC Autosampler device: Standard G1313A instrument. The microwave reaction was conducted on a CEM Discover (0–600 W, 2450 MHz) instrument and the conventional high-pressure reaction was performed on Parr 4590 device. Rotary evaporators were served in the concentration of the reaction solutions under reduced pressure.

(E)-3-(4-amino-3,5-dimethylphenyl)acrylamide (6)

4-Bromo-2,6-dimethylaniline 4 (50 mmol, 10 g), acrylamide 5 (50 mmol, 3.7 g), sodium acetate (75 mmol, 6.15 g), palladium acetate (15 mmol, 3.4 g) and tris(2-methylphenyl)phosphine (15 mmol, 4.6 g) was placed in a round bottom flask, and N,N-dimethylacetamide was slowly added to the round bottom flask under nitrogen, then the mixture was heated to 130 °C for 24 h. After the completion of the reaction, the mixture was cooled to room temperature, filtered over celite, evaporated. The residue was recrystallized in ethyl acetate and petroleum ether to give the product (E)-3-(4-amino-3,5-dimethylphenyl)acrylamide (6), 4.8 g, yield: 51%.

(E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile hydrochloride (2)

To a round-bottomed flask consisting of 10 mL of phosphorus oxychloride was added compound 6 slowly at 0 °C and then refluxed for 8 h at 40 °C. After completion of the reaction was monitored by TLC, and the reaction mixture was slowly poured into the ice-water mixture and stirred for 1 h and then filtered to obtain the crude (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile (7) as white crystal solid.

The obtained crude product 7 was dissolved in anhydrous ethanol, and then added ethanolic hydrochloric acid solution, and stirred for 30 min, then filtered to obtain (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile hydrochloride (2), 5.0 g. Yield: 95%. mp: 78–80 °C. 1H NMR (400 MHz, CDCl3): δ 7.22 (d, J = 16.5 Hz, 1H, CH=), 7.05 (s, 2H, Ph-H), 5.59 (d, J = 16.5 Hz, 1H, =CH), 3.95 (s, 2H, NH), 2.18 (s, 6H, CH3). 13C NMR (100 MHz, CDCl3): δ 150.94, 146.21, 129.86, 128.02, 123.28, 121.50, 119.60, 90.28, 77.38, 77.06, 76.74, 17.50. ESI-MS: m/z 173.54 [M+H]+, C11H12N2 (172.10).

Preparation of ethanolic hydrochloric acid solution

The solvent of anhydrous ethanol was stirred under ice bath, and then 41 mL of acetyl chloride reagent added slowly dropwise and stirred for 30 min to obtain an ethanolic hydrochloric acid solution.

4-((4-hydroxypyrimidin-2-yl)amino)benzonitrile (13)

Starting materials 2-methylthio-4-pyrimidinone 11 (70 mmol, 10 g) and p-aminobenzonitrile 12 (77 mmol, 9.14 g) were taken together, stirred under the inert condition at 160 °C for 2 h and then increased the temperature to 180 °C for 4 h. Then the reaction was allowed to room temperature and added an appropriate amount of N, N-dimethylformamide. The resulted mixture was kept in the ultrasonic vibrator for 30 min. Then the mixture was filtered and washed with acetonitrile and dichloromethane, dried in vacuo to give 4-((4-hydroxypyrimidin-2-yl)amino)benzonitrile (13) as a white solid (10.3 g, yield 70%).

4-((4-chloropyrimidin-2-yl)amino)benzonitrile (3)

Compound 13 was dissolved in 20 mL of phosphorus oxychloride at 0 °C and then refluxed for 1h. After completion, the mixture was cooled to room temperature, slowly poured into 100 g of crushed ice and stirred for half an hour. After filtration, the obtained filter cake was dissolved in 50 mL of water, and the pH was adjusted to 7–8 with potassium carbonate and filtered. The filtrate was washed with acetonitrile and dried to obtain 4-((4-chloropyrimidin-2-yl)amino)benzonitrile (3) as a white solid (9.9 g). Yield: 89%. mp: 209-210 °C. 1H NMR (400 MHz, DMSO-d6): δ 10.58 (s, 1H), 8.55 (d, J = 5.2 Hz, 1H, C6-pyrimidine-H), 7.87 (dd, 4H, Ph-H), 7.13 (d, J = 5.2 Hz, 1H, C6-pyrimidine-H); ESI-MS: m/z 231. 2 [M+H]+, C11H7ClN4 (230.04).

Rilpivirine (1)

A mixture of compound 2 (1 g, 4.8 mmol) and 3 (1.2 g, 5.2 mmol) along with 10 mL acetonitrile was transferred into 20 mL microwave vial and set the reaction temperature at 140 °C, 2 h. After completion, the reaction mixture was cooled to room temperature and then 10% potassium carbonate solution was added dropwise to the vial to adjust the pH to 8–9. The obtained filtrate was washed with acetonitrile to obtain the target molecule rilpivirine as a white solid (1.28 g). Yield 71%. mp: 138–140 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.62 (s, 1H, NH), 8.95 (s, 1H, NH), 7.98 (t, J = 27.2 Hz, 2H, Ph-H), 7.69 (m, 3H, =CH, Ph-H), 7.49 (s, 2H, Ph-H), 6.46 (d, J = 16.7 Hz, 1H, =CH), 2.18 (s, 6H, CH3). ESI-MS: m/z 367.24 [M+H]+, C22H18N6 (366.16).

Availability of data and materials

All data are fully available without restriction.





Human immunodeficiency virus 1


Reverse transcriptase


Non-nucleoside reverse transcriptase inhibitors


Highly active antiretroviral therapy






Acquired immunodeficiency syndrome




Thin layer chromatography


Mass spectra


1H-Nuclear magnetic resonance

13C NMR:

13C-Nuclear magnetic resonance


  1. 1.

    Kang D, Feng D, Ginex T, Zou J, Wei F, Zhao T, Huang B, Sun Y, Desta S, De Clercq E et al (2020) Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. Acta Pharm Sin B 10(5):878–894

    CAS  Article  Google Scholar 

  2. 2.

    Wu Y, Tang C, Rui R, Yang L, Ding W, Wang J, Li Y, Lai CC, Wang Y, Luo R et al (2020) Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors. Acta Pharm Sin B 10(3):512–528

    CAS  Article  Google Scholar 

  3. 3.

    Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X (2013) HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 33(Suppl 1):E1-72

    CAS  Article  Google Scholar 

  4. 4.

    Zhan P, Pannecouque C, De Clercq E, Liu X (2016) Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem 59(7):2849–2878

    CAS  Article  Google Scholar 

  5. 5.

    Das K, Arnold E (2013) HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr Opin Virol 3(2):119–128

    CAS  Article  Google Scholar 

  6. 6.

    Sluis-Cremer N (2018) Future of non-nucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci USA. 115(4):637–638

    CAS  Article  Google Scholar 

  7. 7.

    Kang D, Wang Z, Zhang H, Wu G, Zhao T, Zhou Z, Huo Z, Huang B, Feng D, Ding X et al (2018) Further exploring solvent-exposed tolerant regions of allosteric binding pocket for novel HIV-1 NNRTIs discovery. ACS Med Chem Lett 9(4):370–375

    CAS  Article  Google Scholar 

  8. 8.

    Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, Jin D, Birkus G, Kutty N, Liu X (2010) Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem 53(10):4295–4299

    CAS  Article  Google Scholar 

  9. 9.

    Sharma M, Saravolatz LD (2013) Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother 68(2):250–256

    CAS  Article  Google Scholar 

  10. 10.

    Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A. 105(5):1466–1471

    CAS  Article  Google Scholar 

  11. 11.

    Guillemont JEG, Palandjian P, De Jonge MR, Koymans LMH, Vinkers HM, Daeyaert FFD, Heeres J, Van Aken KJA, Lewi PJ, Janssen PAJ (2003) WO 03016306 Feb 2003

  12. 12.

    Guillemont JEG, Stevens PTA, Copmans AH, Peeters J, Stappers AE, Vandecruys RPG, Stoffels P (2006) US 20060111379 A1 May 2006

  13. 13.

    Schils D, Stappers F, Solberghe G et al (2008) Ligandless Heck coupling between a halogenated aniline and acrylonitrile catalyzed by Pd/C: development and optimization of an industrial-scale Heck process for the production of a pharmaceutical intermediate. Org Process Res Dev 12(3):530–536

    CAS  Article  Google Scholar 

  14. 14.

    Reddy BP, Reddy KR, Reddy DM, Reddy AVN, Krishna BV. (2012) WO 2012147091 Nov2012

  15. 15.

    Spychala J (1997) A facile preparation of N2-arylisocytosines. Synth Commun 27(11):1943–1949

    CAS  Article  Google Scholar 

  16. 16.

    Gu SX, Yang SQ, He QQ, Ma XD, Chen FE, Dai HF, Clercq ED, Balzarini J, Pannecouque C (2011) Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs. Bioorg Med Chem 19(23):7093–7099

    CAS  Article  Google Scholar 

  17. 17.

    Zhou Z, Liu T, Wu G, Kang D, Fu Z, Wang Z, De Clercq E, Pannecouque C, Zhan P, Liu X (2019) Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Org Biomol Chem 17(12):3202–3217

    CAS  Article  Google Scholar 

  18. 18.

    Schils DPR, Stappers AE (2006) WO 2006125809 Nov 2006

  19. 19.

    Schils DPR, Willems JJM, Medaer BPAMJ, Pasquier ETJ, Janssen PAJ, Heeres J, Leenders RGG (2004) WO 2004016581 Feb 2004

  20. 20.

    Hajicek J, Slavikova M, Zebula J (2016) WO 2016116074 (A1) Jul 2016

Download references


We gratefully acknowledge financial support from the National Natural Science Foundation of China (NSFC No. 81973181), Shandong Provincial Key research and development project (Nos. 2017CXGC1401, 2019JZZY021011), National Science and Technology Major Projects for "Major New Drugs Innovation and Development" (2019ZX09301126), Foreign cultural and educational experts Project (GXL20200015001), the Program for Outstanding PhD Candidate of Shandong University, Qilu Young Scholars Program of Shandong University (to Zhan P.) and the Taishan Scholar Program at Shandong Province (to Liu X.Y.).


National Natural Science Foundation of China (NSFC No. 81973181), Shandong Provincial Key research and development project (Nos. 2017CXGC1401, 2019JZZY021011), National Science and Technology Major Projects for "Major New Drugs Innovation and Development" (2019ZX09301126), Foreign cultural and educational experts Project (GXL20200015001), the Program for Outstanding PhD Candidate of Shandong University, Qilu Young Scholars Program of Shandong University (to Zhan P.) and the Taishan Scholar Program at Shandong Province (to Liu X.Y.).

Author information




TZ, JY, ZZ, DK, PZ, and XL conceived the project. TZ, JY and ZZ finished the compounds synthesis and structure confirmation. TZ performed the data analysis. FZ and M.Sc. reviewed and edited the manuscript. DK, PZ and XL provided the resources, supervision and funding assistance. All authors critically evaluated the manuscript prior to submission. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Peng Zhan or Xinyong Liu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

The authors declare that the copyright belongs to the journal.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhang, T., Yang, J., Zhou, Z. et al. The development of an effective synthetic route of rilpivirine. BMC Chemistry 15, 22 (2021).

Download citation


  • Rilpivirine
  • Synthetic optimization
  • Microwave-promoted method
  • HIV
  • Antiviral